EGFR and head and neck squamous cell carcinoma: Like cetuximab, many active Phase I and II trials are being performed to investigate the efficacy and safety of panitumumab as first or second line treatment for HNSCC despite development of some side effects including skin rashes which remains the main issue associated with EGFR-targeted antibodies and has even being considered as a marker for drug efficiency [29,76].